Skip to content
Home/Companies/MedTech/Senzime

Senzime

MedTech·Sweden·Active·3yr hold
Entry
2023
Hold
3yr
Status
Active

Who owns Senzime?

Senzime is a Swedish MedTech company, currently owned by Segulah Medical Acceleration since 2023.

Hand-verified · updated 2026-08-17

Open JSON · CC-BY
Segulah Medical Acceleration
Investor
Segulah Medical Acceleration
Segulah Medical Acceleration · 2021 · Life Sciences VC

Key facts

HQSweden
SectorMedTech
StatusActive

More from Segulah Medical Acceleration

Other portfolio companies in the same fund.

Basic Genomics
Active
BiotechSweden· 2025
Protembis
Protembis
Active
MedTechGermany· 2024
Collective Minds Radiology
Active
HealthTechSweden· 2023
Navinci Diagnostics
Active
BiotechSweden· 2022
CytaCoat
Active
MedTechSweden· 2021
Quanta Dialysis Technologies
Quanta Dialysis Technologies
Active
MedTechUK· 2021

More PE-backed in MedTech

Comparable medtech deals from other GPs.

Acufocus, Inc.
Exited 2023
The Carlyle GroupUS
to Bausch + Lomb
Adicon Holdings Limited
Active
The Carlyle GroupUS
Aesynt
Exited 2016
Francisco PartnersUS
to Omnicell
Alere Medical, Inc.
Active
TA AssociatesUS
Alma Lasers, Ltd.
Alma Lasers, Ltd.
Active
TA AssociatesIsrael
Amedes Group
Active
General AtlanticGermany

Questions

Who owns Senzime?

Senzime is currently owned by Segulah Medical Acceleration, through Segulah Medical Acceleration, since 2023.

When did Segulah Medical Acceleration acquire Senzime?

Segulah Medical Acceleration acquired Senzime in 2023.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue